Five commercially-available antibodies react differentially with allelic forms of human HLA-DR beta chain

Mol Immunol. 2022 Dec:152:106-110. doi: 10.1016/j.molimm.2022.10.008. Epub 2022 Oct 27.

Abstract

Allelic variants of HLA-DRB1 have been associated with a variety of autoimmune and infectious diseases. Although the precise molecular mechanisms by which HLA-DRB1 alleles predispose to a particular disease are currently unclear, it has been shown that mRNA expression levels of HLA-DRB1 are dependent on the different alleles. We aimed to measure HLA-DR beta chain levels in peripheral blood mononuclear cells of individuals carrying HLA-DRB1*03:01/*04:01 and HLA-DRB1*03:01/*15:01 alleles by western blotting, using five commercially-available HLA-DRB antibodies. We observed highly heterogeneous binding of the tested antibodies to the different allelic forms of the HLA-DR beta chain. Overall, we show that current immunological research that employs available antibodies to detect HLA-DR beta chains is biased towards detection of specific variants of the protein; this may cause significant discrepancy in quantification of protein expression in a heterogeneous human population.

Keywords: HLA-DR beta chain; Peripheral blood mononuclear cells; Western blot.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • HLA-DR beta-Chains*
  • HLA-DRB1 Chains / genetics
  • Humans
  • Leukocytes, Mononuclear*

Substances

  • HLA-DRB1 Chains
  • HLA-DR beta-Chains